open.spotify.com
Jerry Silver, a professor at Case Western Reserve University School of Medicine, discusses his groundbreaking research in developing treatments for spinal cord injuries. He explains the Phase 1b/2a trial of NVG-291, a peptide that aids nerve regeneration in spinal cord injury patients, and its FDA approval for use in patients. Silver's research on proteoglycans and their inhibitory properties in the eye and spinal cord laid the foundation for developing treatments. He also discusses the role of chondroitinase in promoting nerve regeneration and the potential of the peptide ISP to block the inhibitory effects of proteoglycans. Silver emphasizes the challenges and setbacks in securing support for his research, including the establishment of NervGen, a company aimed at advancing the peptide treatment. He reflects on the potential for positive outcomes in chronic spinal cord injury cases and the delicate balance required in treatment approaches. Silver's persistence, innovative thinking, and commitment to helping people in the biotech industry are highlighted, along with the potential impact of his discoveries on life-changing conditions.
Jerry Silver, a professor at Case Western Reserve University School of Medicine, discusses his groun